Cargando…

Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases

BACKGROUND: Combination of immunotherapy and chemotherapy is recommended for first line treatment of gastric adenocarcinoma (GC) patients with locally advanced unresectable disease or metastatic disease. However, data regarding the concordance rate between PD-L1 combined positive score (CPS) in prim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Drolaiz H. W., Grabsch, Heike I., Gloor, Beat, Langer, Rupert, Dislich, Bastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587283/ https://www.ncbi.nlm.nih.gov/pubmed/37491637 http://dx.doi.org/10.1007/s00432-023-05142-x

Ejemplares similares

Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers
por: Dislich, Bastian, et al.
Publicado: (2022)

Significance of tumour regression in lymph node metastases of gastric and gastro‐oesophageal junction adenocarcinomas
por: Reim, Daniel, et al.
Publicado: (2020)

Surgical pathology of adenocarcinomas arising around or within the gastroesophageal junction
por: Dislich, Bastian, et al.
Publicado: (2022)

Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination
por: Sundar, Raghav, et al.
Publicado: (2021)

Grading der Tumorregression gastrointestinaler Karzinome nach neoadjuvanter Therapie
por: Liu, Drolaiz, et al.
Publicado: (2021)

Direct prediction of genetic aberrations from pathology images in gastric cancer with swarm learning
por: Saldanha, Oliver Lester, et al.
Publicado: (2022)

Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2016)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis
por: Däster, Silvio, et al.
Publicado: (2020)

Her2-Targeted Therapy Induces Autophagy in Esophageal Adenocarcinoma Cells
por: Janser, Félice A., et al.
Publicado: (2018)

Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study)
por: Ali, Safa Mohammed, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
por: Li, Kang, et al.
Publicado: (2022)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer
por: Yan, Rong, et al.
Publicado: (2019)

Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases
por: Manson, Quirine F., et al.
Publicado: (2018)

Impact of programmed death‐ligand 1 (PD‐L1) positivity on clinical and molecular features of patients with metastatic gastric cancer
por: Shin, Minkyue, et al.
Publicado: (2023)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
por: Zhou, Jiandong, et al.
Publicado: (2022)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer’s Disease and Beyond
por: Dislich, Bastian, et al.
Publicado: (2012)

Programmed death-ligand 1 (PD-L1) expression in various tumor types
por: Grosso, Joseph, et al.
Publicado: (2013)

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
por: Núñez Abad, Martín, et al.
Publicado: (2022)

Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
por: Kowalski, Andrzej, et al.
Publicado: (2021)

A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2018)

The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma
por: Shinchi, Yusuke, et al.
Publicado: (2022)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

Correction: A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas
por: Adams, Olivia, et al.
Publicado: (2019)

CUTANEOUS METASTASES FROM GASTRIC ADENOCARCINOMA
por: Erdemır, Asli Turgut, et al.
Publicado: (2011)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis
por: Hassen, Gashaw, et al.
Publicado: (2022)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6q78cdk8js5ht5cseldmdqvctk